{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:15:05Z","timestamp":1787728505414,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003665","name":"National IT Industry Promotion Agency","doi-asserted-by":"publisher","award":["A0121-23-2335"],"award-info":[{"award-number":["A0121-23-2335"]}],"id":[{"id":"10.13039\/501100003665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024-00348897"],"award-info":[{"award-number":["RS-2024-00348897"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-025-01869-2","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:19:49Z","timestamp":1757189989000},"page":"3921-3937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prediction of cognitive decline and Alzheimer\u2019s disease conversion by a plasma biomarker panel in non-demented individuals"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5555-2588","authenticated-orcid":false,"given":"Min-Koo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Muk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Joo","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"issue":"2","key":"1869_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"AQ Collaborators GBDDF","year":"2022","unstructured":"AQ Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8.","journal-title":"Lancet Public Health"},{"key":"1869_CR2","unstructured":"Gauthier S WC, Servaes S, Morais JA, Rosa-Neto P. : World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. https:\/\/www.alzint.org\/u\/World-Alzheimer-Report-2022.pdf (2022). Accessed 14th November, 2024."},{"issue":"1","key":"1869_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"LK Huang","year":"2023","unstructured":"Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update. J Biomed Sci. 2023;30(1):83. https:\/\/doi.org\/10.1186\/s12929-023-00976-6.","journal-title":"J Biomed Sci"},{"issue":"3","key":"1869_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"1869_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1192\/bjp.bp.105.014779","volume":"189","author":"A Busse","year":"2006","unstructured":"Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry. 2006;189:399\u2013404. https:\/\/doi.org\/10.1192\/bjp.bp.105.014779.","journal-title":"Br J Psychiatry"},{"key":"1869_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.960648","volume":"13","author":"M Casagrande","year":"2022","unstructured":"Casagrande M, Marselli G, Agostini F, Forte G, Favieri F, Guarino A. The complex burden of determining prevalence rates of mild cognitive impairment: a systematic review. Front Psychiatry. 2022;13: 960648. https:\/\/doi.org\/10.3389\/fpsyt.2022.960648.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1869_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000354370","volume":"3","author":"A Ward","year":"2013","unstructured":"Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer\u2019s disease to Alzheimer\u2019s dementia: a systematic review of the literature. Dement Geriatr Cogn Disord Extra. 2013;3(1):320\u201332. https:\/\/doi.org\/10.1159\/000354370.","journal-title":"Dement Geriatr Cogn Disord Extra"},{"issue":"7","key":"1869_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010783.pub3","volume":"7","author":"I Arevalo-Rodriguez","year":"2021","unstructured":"Arevalo-Rodriguez I, Smailagic N, Roque-Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-mental state examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2021;7(7): CD010783. https:\/\/doi.org\/10.1002\/14651858.CD010783.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1869_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324. https:\/\/doi.org\/10.1007\/s00401-021-02275-6.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1869_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1869_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"issue":"7","key":"1869_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0765.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1869_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25(2):277\u201383. https:\/\/doi.org\/10.1038\/s41591-018-0304-3.","journal-title":"Nat Med"},{"issue":"12","key":"1869_CR14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mila-Aloma M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1869_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13(1): 68. https:\/\/doi.org\/10.1186\/s13195-021-00804-9.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1869_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01125-1","volume":"14","author":"P Mohaupt","year":"2022","unstructured":"Mohaupt P, Pons ML, Vialaret J, Delaby C, Hirtz C, Lehmann S. \u03b2-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1): 179. https:\/\/doi.org\/10.1186\/s13195-022-01125-1.","journal-title":"Alzheimers Res Ther"},{"key":"1869_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221920","author":"MK Park","year":"2024","unstructured":"Park MK, Ahn J, Lim JM, Han M, Lee JW, Lee JC, et al. A transcriptomics-based machine learning model discriminating mild cognitive impairment and the prediction of conversion to Alzheimer\u2019s disease. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13221920.","journal-title":"Cells"},{"issue":"1","key":"1869_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13195-020-00654-x","volume":"12","author":"D Shigemizu","year":"2020","unstructured":"Shigemizu D, Mori T, Akiyama S, Higaki S, Watanabe H, Sakurai T, et al. Identification of potential blood biomarkers for early diagnosis of Alzheimer\u2019s disease through RNA sequencing analysis. Alzheimers Res Ther. 2020;12(1):87. https:\/\/doi.org\/10.1186\/s13195-020-00654-x.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1869_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23746-0","volume":"12","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, Stomrud E, et al. Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021;12(1): 3555. https:\/\/doi.org\/10.1038\/s41467-021-23746-0.","journal-title":"Nat Commun"},{"issue":"4","key":"1869_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvado G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80(4):360\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1869_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JAD-230620","volume":"98","author":"BT Nallapu","year":"2024","unstructured":"Nallapu BT, Petersen KK, Lipton RB, Davatzikos C, Ezzati A, Alzheimer\u2019s Disease Neuroimaging I. Plasma biomarkers as predictors of progression to dementia in individuals with mild cognitive impairment. J Alzheimers Dis. 2024;98(1):231\u201346. https:\/\/doi.org\/10.3233\/JAD-230620.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1869_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12621","volume":"16","author":"V Devanarayan","year":"2024","unstructured":"Devanarayan V, Llano DA, Hu YH, Hampel H, Kramer L, Dhadda S, et al. Plasma pTau181 enhances the prediction of future clinical decline in amyloid-positive mild cognitive impairment. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2024;16(3): e12621. https:\/\/doi.org\/10.1002\/dad2.12621.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"4","key":"1869_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","volume":"69","author":"XN Shen","year":"2023","unstructured":"Shen XN, Huang SY, Cui M, Zhao QH, Guo Y, Huang YY, et al. Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression. Clin Chem. 2023;69(4):411\u201321. https:\/\/doi.org\/10.1093\/clinchem\/hvad018.","journal-title":"Clin Chem"},{"issue":"1","key":"1869_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging. 2021;1(1):114\u201323. https:\/\/doi.org\/10.1038\/s43587-020-00003-5.","journal-title":"Nat Aging"},{"issue":"6","key":"1869_CR25","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging I, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342. https:\/\/doi.org\/10.1038\/s41591-021-01348-z.","journal-title":"Nat Med"},{"issue":"1","key":"1869_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"6","key":"1869_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"4","key":"1869_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","volume":"6","author":"PK Crane","year":"2012","unstructured":"Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6(4):502\u201316. https:\/\/doi.org\/10.1007\/s11682-012-9186-z.","journal-title":"Brain Imaging Behav"},{"issue":"3","key":"1869_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1037\/0033-2909.114.3.552","volume":"114","author":"SP Reise","year":"1993","unstructured":"Reise SP, Widaman KF, Pugh RH. Confirmatory factor analysis and item response theory: two approaches for exploring measurement invariance. Psychol Bull. 1993;114(3):552\u201366. https:\/\/doi.org\/10.1037\/0033-2909.114.3.552.","journal-title":"Psychol Bull"},{"issue":"4","key":"1869_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","volume":"6","author":"LE Gibbons","year":"2012","unstructured":"Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517\u201327. https:\/\/doi.org\/10.1007\/s11682-012-9176-1.","journal-title":"Brain Imaging Behav"},{"key":"1869_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells13131085","author":"MK Park","year":"2024","unstructured":"Park MK, Ahn J, Kim YJ, Lee JW, Lee JC, Hwang SJ, et al. Predicting longitudinal cognitive decline and Alzheimer\u2019s conversion in mild cognitive impairment patients based on plasma biomarkers. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13131085.","journal-title":"Cells"},{"issue":"4","key":"1869_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"1869_CR33","doi-asserted-by":"publisher","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","DOI":"10.1016\/j.jalz.2011.03.005"},{"issue":"9","key":"1869_CR34","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1002\/alz.13116","volume":"19","author":"J Wang","year":"2023","unstructured":"Wang J, Chen M, Masters CL, Wang YJ. Translating blood biomarkers into clinical practice for Alzheimer\u2019s disease: challenges and perspectives. Alzheimers Dement. 2023;19(9):4226\u201336. https:\/\/doi.org\/10.1002\/alz.13116.","journal-title":"Alzheimers Dement"},{"issue":"17","key":"1869_CR35","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-59. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"issue":"13","key":"1869_CR36","doi-asserted-by":"publisher","first-page":"e1315","DOI":"10.1212\/WNL.0000000000200035","volume":"98","author":"JL Ebenau","year":"2022","unstructured":"Ebenau JL, Pelkmans W, Verberk IMW, Verfaillie SCJ, van den Bosch KA, van Leeuwenstijn M, et al. Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology. 2022;98(13):e1315-26. https:\/\/doi.org\/10.1212\/WNL.0000000000200035.","journal-title":"Neurology"},{"issue":"1","key":"1869_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01340-4","volume":"15","author":"Z Yang","year":"2023","unstructured":"Yang Z, Sreenivasan K, Toledano Strom EN, Osse AML, Pasia LG, Cosme CG, et al. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer\u2019s disease. Alzheimers Res Ther. 2023;15(1): 190. https:\/\/doi.org\/10.1186\/s13195-023-01340-4.","journal-title":"Alzheimers Res Ther"},{"key":"1869_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417361","author":"S Lehmann","year":"2023","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Blanc F, Paquet C, Allinquant B, et al. Blood neurofilament levels predict cognitive decline across the Alzheimer\u2019s disease continuum. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242417361.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1869_CR39","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2105\/ajph.88.9.1337","volume":"88","author":"R Brookmeyer","year":"1998","unstructured":"Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer\u2019s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337\u201342. https:\/\/doi.org\/10.2105\/ajph.88.9.1337.","journal-title":"Am J Public Health"},{"issue":"3","key":"1869_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement. 2007;3(3):186\u201391. https:\/\/doi.org\/10.1016\/j.jalz.2007.04.381.","journal-title":"Alzheimers Dement"},{"key":"1869_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/frdem.2023.1271680","author":"H Ding","year":"2023","unstructured":"Ding H, Wang B, Hamel AP, Melkonyan M, Ang TFA, Alzheimer\u2019s Disease Neuroimaging I, et al. Prediction of progression from mild cognitive impairment to Alzheimer\u2019s disease with longitudinal and multimodal data. Front Dement. 2023. https:\/\/doi.org\/10.3389\/frdem.2023.1271680.","journal-title":"Front Dement"},{"issue":"1","key":"1869_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12307","volume":"14","author":"V Dore","year":"2022","unstructured":"Dore V, Doecke JD, Saad ZS, Triana-Baltzer G, Slemmon R, Krishnadas N, et al. Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer\u2019s continuum. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2022;14(1): e12307. https:\/\/doi.org\/10.1002\/dad2.12307.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01869-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01869-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01869-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:10:49Z","timestamp":1783764649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01869-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01869-2","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}